关键词：乳腺癌；癌细胞；组织生长；失控； HER-2阳性乳腺癌
摘 要：Breast cancer is characterized by uncontrolled growth of cancerous cells in the tissues of the breast. Though both males and females are affected by the disease, male breast cancer is rare. Breast cancer is the second most common form of cancer in the world. Histologically, the disease can be classified as ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinomas. Ductal carcinoma originates in the lining of the milk ducts while lobular carcinoma arises in the milk glands of the breast. The proliferation of cancerous cells from the site of origin to surrounding tissues is known as invasive breast cancer. Invasive ductal carcinoma is the most common subtype, accounting for 70-80 percent of all cases. According to a 2012 report by the GLOBOCAN project, breast cancer accounted for 11.90 percent of the total cancer cases and led to 522,000 deaths worldwide. Breast cancer that tests positive for the HER-2 protein, which affects the growth of the malignant cells, is known as HER-2 positive breast cancer. This protein is mostly found on the surface of normal breast cells, and their uncontrolled synthesis stimulates the growth of malignant cells. HER-2 positive breast cancer spreads and metastasizes more rapidly than HER-2 negative breast cancer. HER-2 positive breast cancer accounts for 20-25 percent of all types of breast cancer cases diagnosed in the US.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Disease Overview

06.1 Understanding the Disease

06.2 Pathophysiology

06.3 Epidemiology

06.4 Diagnosis

IHC

FISH

SPoT-Light HER-2 CISH Test

Inform HER-2 Dual ISH Test

06.5 Management

Surgery

Radiotherapy

Chemotherapy

Targeted Therapy

Hormonal Therapy

06.6 Economic Burden

07. Pipeline Analysis

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 HER-2 Positive Breast Cancer Market in US

Market Size and Forecast

08.4 HER-2 Positive Breast Cancer Market in EU

Market Size and Forecast

08.5 Five Forces Analysis

09. Market Segmentation by Type of Therapy

09.1 Global HER-2 Positive Breast Cancer Market by

Type of Therapy 2014-2019

09.2 Chemotherapy

Alkylating Agents

Antimetabolites

Cytotoxic Antibiotics

Taxanes

09.3 Targeted Therapy

09.4 Hormone Therapy

10. Market Segmentation by Molecule Type

10.1 Global HER-2 Positive Breast Cancer Market by

Molecule Type 2014-2019

10.2 Biologics

10.3 Small Molecules

11. Market Segmentation by Route of

Administration

11.1 Global HER-2 Positive Breast Cancer Market by

Route of Administration 2014-2019

11.2 Oral

11.3 Parenteral

12. Geographical Segmentation

12.1 Global HER-2 Positive Breast Cancer Market by

Geographical Segmentation 2014-2019

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

20.1 Competitive Scenario

Key News

Mergers and Acquisitions

20.2 Vendor Ranking 2014

Competitive Assessment of Top Drugs

Celgene

F. Hoffmann-La Roche

GlaxoSmithKline

Novartis

Sanofi

20.3 SWOT Analysis of Targeted Therapies

Herceptin

Kadcyla

Perjeta

Tykerb

20.4 Other Prominent Vendors

21. Key Vendor Analysis

21.1 Celgene

Key Facts

Business Overview

Business Strategy

Business Segmentation by Revenue

Sales by Geography

Key Information

SWOT Analysis

21.2 F. Hoffmann-La Roche

Key Facts

Business Overview

Business Segmentation

Business Segmentation by Revenue 2012 and 2013

Sales by Geography

Business Strategy

Key Information

SWOT Analysis

21.3 GlaxoSmithKline

Key Facts

Business Overview

Business Segmentation

Business Segmentation by Revenue 2012 and 2013

Sales by Geography

Pipeline Products

Business Strategy

Key Information

SWOT Analysis

21.4 Novartis

Key Facts

Business Description

Business Segmentation

Revenue by Business Segmentation

Revenue Comparison 2012 and 2013

Sales by Geography

Business Strategy

Key Developments

SWOT Analysis

21.5 Sanofi

Key Facts

Business Description

Business Segmentation

Revenue by Business Segmentation

Revenue Comparison 2012 and 2013

Sales by Geography

Business Strategy

Key Developments

SWOT Analysis

22. Other Reports in this Series